ORIGINAL RESEARCH

Prognostic Impact of Myocardial Extracellular Volume Fraction Assessment Using Dual-Energy Computed Tomography in Patients Treated With Aortic Valve Replacement for Severe Aortic Stenosis

Masataka Suzuki, MD; Takayoshi Toba, MD, PhD; Yu Izawa, MD; Hiroshi Fujita, MD; Keisuke Miwa, MD; Yu Takahashi, MD; Hiroyuki Toh, MD; Hiroyuki Kawamori, MD, PhD; Hiromasa Otake, MD, PhD; Hidekazu Tanaka, MD, PhD; Sei Fujimura, MD, PhD; Yoshiaki Watanabe, MD, PhD; Atsushi K. Kono, MD, PhD; Kenji Okada, MD, PhD; Ken-ichi Hirata, MD, PhD

BACKGROUND: Myocardial extracellular volume fraction (ECV), measured by cardiac magnetic resonance imaging, is a useful prognostic marker for patients who have undergone aortic valve replacement (AVR) for aortic stenosis. However, the prognostic significance of ECV measurements based on computed tomography (CT) is unclear. This study evaluated the association between ECV measured with dual-energy CT and clinical outcomes in patients with aortic stenosis who underwent transcatheter or surgical AVR.

METHODS AND RESULTS: We retrospectively enrolled 95 consecutive patients (age, 84.0±5.0 years; 75% women) with severe aortic stenosis who underwent preprocedural CT for transcatheter AVR planning. ECV was measured using iodine density images obtained by delayed enhancement dual-energy CT. The primary end point was a composite outcome of all-cause death and hospitalization for heart failure after AVR. The mean ECV measured with CT was 28.1±3.8%. During a median follow-up of 2.6 years, 22 composite outcomes were observed, including 15 all-cause deaths and 11 hospitalizations for heart failure. In Kaplan-Meier analysis, the high ECV group (≥27.8% [median value]) had significantly higher rates of composite outcomes than the low ECV group (<27.8%) (log-rank test, P=0.012). ECV was the only independent predictor of adverse outcomes on multivariable Cox regression analysis (hazards ratio, 1.25; 95% CI, 1.10–1.41; P<0.001).

CONCLUSIONS: Myocardial ECV measured with dual-energy CT in patients who underwent aortic valve intervention was an independent predictor of adverse outcomes after AVR.

Key Words: aortic stenosis ■ computed tomography ■ extracellular volume fraction

Aortic stenosis (AS) is a progressive disease of the myocardium, as well as the aortic valve itself, which causes continuous pressure overload on the left ventricle, leading to cardiac remodeling, myocardial hypertrophy, and finally myocardial fibrosis,1 a key determinant of cardiac dysfunction in patients with severe AS.2,3 As the disease progresses, the pathological changes, including fibrotic replacement, become uncontrollable, even by aortic valve replacement (AVR), resulting in further impaired cardiac function and poor...
CLINICAL PERSPECTIVE

What Is New?
- Myocardial extracellular volume fraction, derived from dual-energy computed tomography, was the independent predictor for composite outcomes of all-cause death and hospitalization for heart failure in patients with severe aortic stenosis who underwent transcatheter or surgical aortic valve replacement.

What Are the Clinical Implications?
- In transcatheter aortic valve replacement candidates, myocardial extracellular volume fraction measurement with dual-energy computed tomography is valuable for predicting prognosis after aortic valve replacement and reasonable because it can be easily measured by adding delayed myocardial enhancement imaging to the routine preprocedural computed tomography imaging.

Nonstandard Abbreviations and Acronyms

| Abbreviation | Definition                                  |
|--------------|---------------------------------------------|
| AS           | aortic stenosis                              |
| AVR          | aortic valve replacement                     |
| E            | early diastolic transmitral flow velocity    |
| e'           | early diastolic mitral annular velocity      |
| ECV          | extracellular volume fraction                |
| SAVR         | surgical aortic valve replacement            |
| STS-PROM     | Society of Thoracic Surgeons Predicted Risk of Mortality |
| TAVR         | transcatheter aortic valve replacement       |

Contrast-enhanced computed tomography (CT) can be an alternative approach to CMR for measuring ECV, because of technological advances in CT, such as dual-energy CT, and technical improvement of CT scanning methods based on the pharmacokinetics of iodinated contrast materials. Recent studies have suggested that ECV can be successfully measured using single-energy as well as dual-energy CT, with good agreement with CMR findings. Furthermore, particularly in candidates for transcatheter AVR (TAVR), CT is more useful for evaluating ECV than CMR, because it can be measured by simply adding delayed myocardial enhancement imaging to the routine preprocedural CT used for assessing the anatomical suitability for TAVR. Accordingly, CT assessment of ECV may facilitate risk stratification and prognostic prediction in TAVR candidates.

Currently, there are no data on the prognostic value of CT-based ECV measurement in patients with severe AS. Thus, this study measured ECV in dual-energy CT for TAVR planning in patients with severe AS and evaluated the association between ECV and post-AVR clinical outcomes.

METHODS

The data that support the findings of this study are available from the corresponding author on reasonable request.

Study Design

This single-center cohort study retrospectively enrolled consecutive patients with severe AS who underwent CT angiography for TAVR planning between January 2015 and March 2018 at Kobe University Hospital. Patients underwent TAVR or surgical AVR (SAVR) after comprehensive clinical evaluation by a designated heart team following established guidelines. The following exclusion criteria were used: inadequate image quality attributable to artefacts and underuse of contrast agents attributable to advanced renal failure.

The study protocol adhered to the tenets of the 1975 Declaration of Helsinki. We provided patients with an appropriate opportunity to decline consent under the opt-out method on the institutional website; the requirement for written informed consent was waived. The study was approved by the institutional ethical committee of Kobe University Graduate School of Medicine.

CT Image Acquisition and Analysis

All image acquisitions were performed using a commercially available third-generation dual-source CT scanner (SOMATOM Force, Siemens Healthcare,
Forchheim, Germany). First, a noncontrast prospective electrocardiographic triggering CT scan for calcium scoring was performed with the following parameters at cardiac phase of 65%: collimation, 104–192×0.6 mm; tube voltage, 120 kV; and tube current, 80 mA. Images for calcium scoring were reconstructed with a 3-mm slice thickness. Next, standard electrocardiographic-triggering CT angiography for TAVR planning was performed using 12 mL of contrast agent (Iopamiron 370, 370 mg/mL; Bayer Yakuhin, Osaka, Japan) to assess the contrast agent transit time, using 0.6 mL/kg of contrast agent at a flow rate of 0.06 mL/kg per second, followed by 0.6 mL/kg diluted contrast (1:1; contrast/physiological saline) at the same flow rate used for angiography. Delayed enhancement image acquisition was performed 5 minutes after CT angiography, using a prospective electrocardiographic-triggering dual-energy scan with the following parameters: cardiac phase, 25% systole; collimation, 128×0.6 mm; tube voltage and current, 90/150 kV, with tin filtration and 250/192 mA/rotation; gantry rotation time, 250 ms; and pitch factor, 0.15. The axial image data were reconstructed using the following parameters: slice thickness, 1 mm; slice interval, 1 mm; and field of view, 240 mm. Delayed enhancement image was obtained routinely in the patients who underwent CT angiography for pre-TAVR assessment. β-Blockers and/or nitrates were not routinely used for premedication, because of hemodynamic concerns in severe AS. Aortic valve calcium score was measured on a commercially available workstation (Ziostation2 version 2.4.2.3, Ziosoft Inc, Tokyo, Japan) using the Agatston method and was expressed in arbitrary units.

**ECV Measurement**

ECV was measured on a commercially available workstation (syngo.via VB10A, Siemens Healthcare, Forchheim, Germany). Iodine maps were obtained from 150-kV (with tin filtration) and 90-kV images on the workstation by using postprocessing software (heart PBV, Siemens Healthcare), based on the 3-material decomposition method (Figure 1A through 1C). After the iodine map images were reformatted to the short-axis plane with 5-mm section thickness, regions of interest were manually drawn on the myocardium, according to the American Heart Association’s 16-segment model of the left ventricle, to measure the iodine density in the myocardium (Figure 1D). A circular region of interest (at least 100 mm²) was drawn in the left ventricular (LV) cavity to measure the iodine density in the blood pool. In iodine map images, iodine density was expressed in mg/mL. ECV was calculated using the following equation: ECV (%)=(1−hematocrit)×(iodine density in myocardium)/(iodine density in blood pool)×100.

**Echocardiographic Measurement**

Commercially available echocardiography systems were used for this study. All parameters were measured using the current American Society of Echocardiography and European Association of Echocardiography guidelines. The LV ejection fraction (LVEF) was measured using the modified Simpson method. LV mass was calculated with the cube formula. The early diastolic transmitral flow velocity (E) was measured using pulsed-wave Doppler echocardiography. Spectral pulsed-wave Doppler-derived early diastolic mitral annular velocity (e') was obtained by averaging the septal and lateral mitral annular velocity, and the E/e' ratio was calculated. The peak aortic-jet velocity was measured using continuity-wave Doppler mode. The aortic valve mean gradient was determined by tracing the velocity-time integral of the transaortic valvar flow, which was measured by using continuous-wave Doppler mode. The aortic valvar orifice area was calculated by the continuity equation and then indexed to the body surface area. The low-flow, low-gradient subtype included both the classic and paradoxical low-flow, low-gradient subtype.

**Study End Point**

The primary end point of this study was a composite outcome of all-cause death and hospitalization for heart failure after AVR. The secondary end points were all-cause death, cardiac death, or hospitalization for heart failure. A standard definition was used to examine clinical events related to hospitalization for heart failure. Cardiac death was defined as death attributable to myocardial ischemia and infarction, heart failure, or cardiac arrest resulting from arrhythmia or unknown cause. Clinical events were assessed by review of electronic medical records, reports from family members, and telephone interviews. The first event (death or hospitalization for heart failure) in each patient served as the clinical end point of interest.

**Statistical Analysis**

The normality of data distribution of all continuous variables was assessed using the Shapiro-Wilk test. Continuous variables are expressed as means±SD or median (interquartile range [IQR]), as appropriate, and were compared using Student t-test or the Mann-Whitney U test. Categorical variables are expressed as counts and percentages and were compared using χ² or Fisher exact tests. The correlation was evaluated by using the Pearson or Spearman correlation coefficient appropriately.

Twenty randomly chosen participants were used to evaluate intraobserver and interobserver reliabilities.
of ECV measurements using the intraclass correlation coefficient and Bland-Altman plot.
For the time-to-event analyses, cumulative incidence curves were constructed with the use of the Kaplan-Meier method, and the event rates were compared using the log-rank test. Competing-risk cumulative incidence method was used to estimate the cumulative risk of hospitalization for heart failure, and the Gray test was used to compare the study groups because death without evidence of hospitalization for heart failure was considered as a competing risk in the analysis. Univariable Cox regression analysis was performed to determine which variables were associated with the composite outcome. The significant variables on univariable analysis were included in the multivariable Cox regression model.

The statistical analyses were performed using JMP version 14.2.0 (SAS Institute, Cary, NC) and R version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria). *P*<0.05 was considered statistically significant.

**RESULTS**

**Study Population**
A total of 147 patients with severe AS underwent CT angiography for TAVR planning during the study period. After excluding 33 patients who did not take the intervention for the aortic valve, we excluded 19 patients because of artefact-related inadequate image quality (n=10), low-contrast agent usage attributable to impaired renal function (n=7), or unavailable images.
(n=2). Thus, 95 patients (mean age, 84.0±5.0 years; 75% women) were studied (Figure 2). The median Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score was 5.85% (IQR, 4.39%–9.43%). The proportions of patients who underwent TAVR and SAVR were 78% and 22%, respectively. In the subgroup analysis, the SAVR group had a higher STS-PROM score than the TAVR group (7.93% [IQR, 5.28%–11.88%] versus 5.67% [IQR, 4.33%–9.05%]; \( P=0.049 \)) (Table S1).

**ECV Assessment With Dual-Energy CT**

Mean ECV was 28.1±3.8%. ECV data were normally distributed, with the mean approximately equal to the median (27.8%) (Figure 3). There is high variability in the number of patients clustering between 24% and 30% ECV values. The intraclass correlation coefficients for the intraobserver and interobserver measurements of the ECV were 0.965 and 0.930, respectively. In Bland-Altman plots, the mean intraobserver and interobserver differences were −0.19% (95% limit of agreement, −1.62% to 1.24%) and 0.40% (95% limit of agreement, −1.63% to 2.42%), respectively (Figure 4).

CT scans were performed at a median of 42 days (IQR, 18–69 days) before AVR. The median interval between the blood test and CT scan was 0 days (IQR, 0–3 days). At CT acquisition, the mean heart rate was 68±14 beats/min. Mean effective radiation doses of dual-energy scans and mean contrast material volume per body weight were 4.7±2.0 mSv and 0.93±0.26 mL/kg, respectively.

**Comparison of Patient Data between Low and High ECV**

Patients were divided into low and high ECV groups, based on the median ECV (Table 1). Mean ECV was 25.2±2.0% and 30.9±2.8% in the low and high ECV groups, respectively (\( P<0.001 \)). Age and sex were similar in both groups. Body mass index and hematocrit values were significantly lower in the high ECV group, which also had a higher New York Heart Association class and B-type natriuretic peptide levels. Among the echocardiographic parameters, the high ECV group
had lower LVEF and higher E/e’. However, the 2 groups had similar echocardiographic measurements related to AS severity, such as transaortic valvar mean pressure gradient. There were no significant differences in the treatment approach.

Correlation of ECV With LV Decompensation and Severity of AS

Scattergrams indicating the correlation of ECV with measurements related to LV decompensation and AS severity are shown in Figure 5. ECV was significantly positively correlated with B-type natriuretic peptide (r=0.395; P<0.001) and the E/e’ ratio (r=0.223; P=0.038) and negatively correlated with LVEF (r=−0.251; P=0.014) (Figure 5A through 5C). There was no significant correlation between ECV and echocardiographic parameters related to AS severity and the aortic valve calcium score (Figure 5D through 5F).

Relationship between ECV and Clinical Events

During a median follow-up of 2.6 years (IQR, 1.9–3.3 years) after AVR, 22 (23%) the composite outcome occurred, including 15 (16%) all-cause deaths, 6 (6%) cardiac deaths, and 11 (12%) hospitalizations for heart failure. Two deaths occurred within 30 days of AVR. In Kaplan-Meier analysis, the high ECV group had significantly higher rates of all-cause mortality and hospitalizations for heart failure than the low ECV group (P=0.012) (Figure 6A). All-cause mortality was significantly higher in the high than in the low ECV group (P=0.009) (Figure 6B). Cardiac death and hospitalization for heart failure occurred more frequently in the high ECV group, but this was not statistically significant (P=0.078 and P=0.11, respectively) (Figure 6C and 6D). In the univariable analysis, New York Heart Association class III or IV, atrial fibrillation, and ECV were significantly associated with the composite outcomes (Table 2). In the multivariable Cox regression analysis, only ECV was independently associated with the composite outcomes (hazards ratio, 1.25; 95% CI, 1.10–1.41; P<0.001). In the subgroup analysis between TAVR and SAVR groups, ECV in each group was also significantly associated with the composite outcomes (Tables S2 and S3).

DISCUSSION

In the current study, we measured ECV using the iodine-density method with delayed enhancement dual-energy CT images. We demonstrated significant correlation of ECV with laboratory and echocardiographic findings related to LV decompensation, as well as significant association between ECV and clinical outcomes in patients with severe AS who underwent AVR. Furthermore, ECV was the only independent predictor of all-cause death and hospitalization for heart failure.

ECV Measurement Using Dual-Energy CT

Recent research studies have suggested that contrast-enhanced CT can be an alternative to CMR for measuring ECV. Although CMR is a well-established modality for evaluating ECV and produces excellent soft tissue contrast without radiation exposure, it has several limitations, such as a longer acquisition time, limited scan slices, and contraindication in patients with claustrophobia or implanted pacemaker. Meanwhile, contrast-enhanced CT, although it requires some radiation exposure, has high spatial and temporal resolutions; besides, the soft tissue contrast has improved because of advancements in CT scanners and scanning methods. Particularly in TAVR candidates, ECV can be measured by simply adding a dual-energy CT image during routine acquisition of delayed enhancement preprocedural CT images, with...
### Table 1. Patient Characteristics

| Characteristics                        | All patients | Low ECV group | High ECV group | P value  |
|----------------------------------------|--------------|---------------|----------------|----------|
|                                        | (n=95)       | (n=47)        | (n=48)         |          |
| Age, y                                 | 84.0±5.0     | 84.5±4.3      | 83.5±6.6       | 0.34     |
| Female sex, n (%)                      | 71 (75)      | 35 (74)       | 36 (75)        | 0.95     |
| Body mass index, kg/m²                 | 22.6±3.8     | 23.6±3.6      | 21.5±3.7       | 0.006*   |
| Body surface area, m²                  | 1.42±0.16    | 1.44±0.17     | 1.40±0.16      | 0.23     |
| Clinical status                        |              |               |                |          |
| NYHA class III or IV                   | 30 (32)      | 8 (17)        | 22 (46)        | 0.002*   |
| STS-PROM score, %                      | 5.85 (4.39–9.43) | 5.67 (4.22–9.24) | 6.45 (4.49–9.89) | 0.58     |
| Medical history, n (%)                 |              |               |                |          |
| Hypertension                           | 70 (74)      | 38 (81)       | 32 (67)        | 0.11     |
| Dyslipidemia                           | 35 (37)      | 20 (43)       | 15 (31)        | 0.25     |
| Diabetes                               | 20 (21)      | 10 (21)       | 10 (21)        | 0.96     |
| Chronic kidney disease                 | 39 (41)      | 19 (40)       | 20 (40)        | 0.90     |
| Atrial fibrillation                    | 16 (17)      | 6 (13)        | 10 (21)        | 0.29     |
| Previous PCI                           | 20 (21)      | 8 (17)        | 12 (25)        | 0.34     |
| Previous CABG                          | 2 (2)        | 1 (2)         | 1 (2)          | 0.99     |
| Previous myocardial infarction         | 5 (5)        | 1 (2)         | 4 (8)          | 0.16     |
| Implantable cardiac device             | 2 (2)        | 1 (2)         | 1 (2)          | 0.99     |
| Blood examination findings             |              |               |                |          |
| Hematocrit, %                          | 35.3±4.5     | 36.2±4.2      | 34.4±4.6       | 0.047*   |
| Creatinine, mg/dL                      | 0.85 (0.68–1.01) | 0.87 (0.69–1.06) | 0.84 (0.68–1.00) | 0.63     |
| eGFR, mL/min/1.73 m²                   | 54.6±16.4    | 53.2±16.1     | 56.0±16.8      | 0.41     |
| BNP, pg/mL                             | 268.5 (105.1–512.7) | 159.6 (70.9–308.6) | 358.7 (201.1–655.7) | <0.001* |
| Echocardiographic measures             |              |               |                |          |
| LV end-diastolic volume, mL            | 69.9 (53.4–89.5) | 69.7 (52.0–88.3) | 70.2 (63.8–95.2) | 0.54     |
| LV end-systolic volume, mL             | 24.4 (18.0–36.6) | 23.5 (17.0–34.7) | 26.7 (19.4–38.8) | 0.19     |
| LVEF, %                                | 63.9 (56.0–71.0) | 67.0 (60.6–72.0) | 61.5 (52.3–69.8) | 0.049*   |
| LV mass, g                             | 163.0 (136.4–211.7) | 152.6 (136.4–193.7) | 175.0 (132.4–231.3) | 0.26     |
| E/e' ratio                             | 23.1 (16.3–30.9) | 21.2 (15.7–29.2) | 25.6 (17.6–33.8) | 0.036*   |
| Peak aortic-jet velocity, cm/s         | 451.0 (425.8–491.1) | 449.5 (425.8–492.4) | 459.1 (421.8–490.7) | 0.95     |
| Mean aortic valve gradient, mm Hg      | 51.4±13.4    | 51.5±13.2     | 51.4±13.8      | 0.97     |
| Aortic valve area, cm²                 | 0.61±0.16    | 0.62±0.14     | 0.59±0.19      | 0.27     |
| Indexed aortic valve area, cm²/m²      | 0.43±0.11    | 0.44±0.10     | 0.42±0.13      | 0.53     |
| Bicuspid aortic valve, n (%)           | 7 (7)        | 3 (6)         | 4 (8)          | 0.72     |
| Low-flow, low-gradient subtype, n (%)  | 9 (9)        | 3 (6)         | 6 (13)         | 0.30     |
| CT measures                            |              |               |                |          |
| ECV, %                                 | 28.1±3.8     | 25.2±2.0      | 30.9±2.8       | <0.001*  |
| Aortic valve calcium score, AU         | 2307.1 (1659.4–3308.9) | 2307.1 (1550.0–3259.0) | 2296.3 (1703.4–3376.5) | 0.69     |
| Intervention for aortic valve, n (%)   |              |               |                |          |
| SAVR                                   | 21 (22)      | 12 (26)       | 9 (19)         | 0.43     |
| TAVR                                   | 74 (78)      | 35 (74)       | 39 (81)        |          |

Continuous variables are expressed as mean±SD or median (interquartile range) and were compared using the Student t-test or the Mann-Whitney U test, as appropriate. Categorical variables are expressed as counts and percentages and were compared using χ² or Fisher exact tests. AU indicates Agatston unit; BNP, B-type natriuretic peptide; CABG, coronary artery bypass grafting; CT, computed tomography; E, early diastolic transmitral flow velocity; e', early diastolic mitral annular velocity; ECV, extracellular volume fraction; eGFR, estimated glomerular filtration rate; LV, left ventricular; LVEF, LV ejection fraction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SAVR, surgical aortic valve replacement; STS-PROM, Society of Thoracic Surgeons Predicted Risk of Mortality; and TAVR, transcatheter aortic valve replacement.

*P<0.05.
low additional radiation (4.7±2.0 mSv). It may be appropriate for elderly patients with severe AS who tend not to tolerate CMR because of the long acquisition times and long breath holds. Actually, a few studies have evaluated ECV measured with additional delayed enhancement images on routine preprocedural TAVR-planning CT, and found mean ECV values in patients with severe AS of 28% to 32%, similar to our results.

There are 2 methods for ECV measurement by CT: the subtraction method, using single-energy CT, and the iodine-density method, using dual-energy CT. The subtraction method is a previously validated standard method that requires precontrast and postcontrast equilibrium phase images. This method enables both single- and dual-energy CT scanners to evaluate ECV. However, differentiating between the myocardium and blood on precontrast CT images is challenging, leading to misregistration of precontrast and postcontrast images. In contrast, the iodine-density method uses only the equilibrium-phase iodine density images generated by dual-energy CT images. These images show the spread of iodine in a voxel at a state of equilibrium, and ECV can be measured without the need for precontrast images. We measured ECV using the iodine-density method with delayed enhancement dual-energy CT images and found the method to be highly reproducible (interobserver intraclass correlation coefficient, 0.930). The iodine-density method can reduce radiation dose because it alleviates the need for precontrast images. Moreover, dual-energy CT allows improvement in the signal/noise ratio by using virtual monoenergetic images and iodine maps compared with single-energy CT. In addition, the iodine-density method is reportedly more reliable as a diagnostic modality for myocardial fibrosis. Emoto et al measured ECV using 2 CT-based methods and compared these measurements with the CMR method. The iodine-density method was more accurate than the subtraction method, using CMR as the reference standard method. Therefore, we adopted the iodine-density method in dual-energy CT in the current study.

**Figure 5.** Scattergram indicating correlation of extracellular volume fraction (ECV) with B-type natriuretic peptide (BNP) (A), left ventricular ejection fraction (LVEF) (B), early diastolic transmitral flow velocity (E)/early diastolic mitral annular velocity (e') ratio (C), mean aortic valve (AV) gradient (D), indexed AV area (E), and AV calcium score (F). BNP, LVEF, and E/e' ratio were significantly correlated with ECV, whereas there was no significant correlation between ECV and parameters related to aortic stenosis severity. AU indicates Agatston unit.
Clinical Significance of ECV Assessment

In the present study, ECV measured with CT was significantly associated with New York Heart Association class and B-type natriuretic peptide. Similarly, several studies showed that ECV measured with CMR correlated positively with NT-proBNP (N-terminal pro-B-type natriuretic peptide) and was significantly associated with clinical symptoms, expressed as New York Heart Association class and 6-minute walk test distance, in patients with severe AS. Furthermore, we demonstrated that ECV and echocardiographic measurements of LVEF and the E/e’ ratio, indicating both systolic and diastolic dysfunction, correlated significantly. Previous studies have reported that higher ECV measured with CMR was significantly associated with lower LVEF and higher E/e’ ratio in patients with severe AS, in agreement with our study results. Taken together, these findings imply that ECV could be a composite marker indicating both hormonal and hemodynamic abnormalities in patients with AS.

Interestingly, ECV measured with CT was not significantly associated with the severity of AS, as determined in transthoracic echocardiogram and CT. Several clinical studies have suggested that ECV measured with CMR was not associated with echocardiographic parameters, reflecting the severity of AS in patients undergoing AVR. The authors speculated that this is because AS progression leads to myocardial fibrosis and LV dysfunction, which decrease the aortic valve pressure gradient. However, this cannot explain the lack of significant correlation between ECV and the aortic valve calcium score in the current study. This score, the gold standard for evaluating the severity of low-flow, low-gradient AS, was reported to be significantly associated with the severity of AS, irrespective of cardiac systolic function. To date, no association...
between ECV and the aortic valve calcium score has been reported. Given that the ECV is irrelevant to AS severity, our findings implied that the ECV might reflect cardiac impairment not only because of severe AS, but also because of unspecified cardiomyopathies, such as cardiac amyloidosis, hypertrophic cardiomyopathy, myocardial inflammation, and myocardial infarction, which elevate ECV by causing alterations in the extracellular component of the myocardium. In particular, cardiac amyloidosis is concomitantly observed in 14% to 16% of TAVR candidates. A recent article demonstrated that ECV derived from CT can detect dual AS-amyloid pathology in TAVR candidates. From this perspective, our results might suggest that patients with AS with higher ECV have a higher probability of concomitant cardiac amyloidosis, and thus a poor prognosis.

Prognostic Impact of ECV Measurement

ECV measured with CT was the only independent predictor of composite outcomes of all-cause death and hospitalization for heart failure in the present study. Histological studies reported that the degree of myocardial fibrosis at the time of AVR was significantly associated with the degree of LV functional improvement and clinical outcomes, including mortality and symptoms of heart failure. In previous analysis of the association between CMR-determined ECV and adverse outcomes in patients with AS, ECV was closely related to all-cause death and heart failure, although it was not significant, because of relatively small sample sizes. More recently, Everett et al conducted an international multicenter study to evaluate the association between CMR-determined ECV and clinical outcomes after AVR in 440 patients with severe AS. They found that ECV was independently associated with all-cause mortality after AVR after adjustment for various well-established prognostic markers, including age, sex, and LVEF, consistent with our results. To the best of our knowledge, no previous investigation has demonstrated the significant association between ECV, measured by the iodine-density method using dual-energy CT, and clinical outcomes in patients with AS.

| Characteristics                  | Univariable analysis | Multivariable analysis |
|----------------------------------|----------------------|------------------------|
|                                  | HR 95% CI | P value | HR 95% CI | P value |
| Age, y                           | 1.03 | 0.94–1.13 | 0.55 | |
| Male sex                         | 1.30 | 0.53–3.19 | 0.58 | |
| Body mass index, kg/m²           | 0.90 | 0.79–1.01 | 0.071 | |
| NYHA class III or IV             | 2.79 | 1.20–6.46 | 0.019* | 1.18 | 0.45–3.09 | 0.74 |
| STS-PROM score, %                | 1.05 | 0.96–1.15 | 0.27 | |
| Atrial fibrillation              | 2.89 | 1.18–7.11 | 0.032* | 1.86 | 0.69–5.04 | 0.23 |
| Coronary artery disease          | 0.72 | 0.28–1.84 | 0.48 | |
| Implantable cardiac device       | 2.23 | 0.28–17.47 | 0.49 | |
| BNP, pg/mL                       | 1.00 | 0.99–1.00 | 0.073 | |
| LVEF, %                          | 0.99 | 0.96–1.02 | 0.50 | |
| LV mass, g                       | 1.00 | 0.99–1.01 | 0.81 | |
| E/e' ratio                       | 1.01 | 0.98–1.04 | 0.39 | |
| Mean aortic valve gradient, mm Hg| 1.00 | 0.97–1.04 | 0.79 | |
| Indexed aortic valve area, cm²/m² | 7.30 | 0.19–289.6 | 0.28 | |
| Bicuspid aortic valve            | 0.53 | 0.07–3.92 | 0.49 | |
| Low-flow, low-gradient subtype   | 1.56 | 0.46–5.29 | 0.50 | |
| ECV, %                           | 1.29 | 1.15–1.44 | <0.001* | 1.25 | 1.10–1.41 | <0.001* |
| Aortic valve calcium score, AU   | 1.00 | 0.99–1.00 | 0.58 | |
| TAVR                             | 1.95 | 0.61–6.22 | 0.23 | |

Univariable Cox regression analysis was performed to identify the variables that were associated with the composite outcome. Significant variables identified in the univariable analysis were included in the multivariable Cox regression model. Coronary artery disease defined as history of previous myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. AU indicates Agatston unit; BNP, B-type natriuretic peptide; CI, confidence interval; E, early diastolic transmitral flow velocity; e', early diastolic mitral annular velocity; ECV, extracellular volume fraction; HR, hazard ratio; LV, left ventricular; LVEF, LV ejection fraction; NYHA, New York Heart Association; STS-PROM, Society of Thoracic Surgeons Predicted Risk of Mortality; and TAVR, transcatheter aortic valve replacement.

* P<0.05.
significantly associated with the primary end point in the SAVR group, although not in the TAVR group. The STS-PROM score is one of the well-established prognostic indicators following AVR. However, contrary to our findings, recent Japanese cohort studies have demonstrated that the STS-PROM score has predictive power for clinical outcomes in older Japanese patients treated with TAVR.\(^3\)\(^2\)\(^3\) In our study, we noted a higher incidence of primary end point in patients undergoing TAVR with high STS-PROM score, although this tendency was not statistically significant. If the sample size was larger, the STS-PROM score might have been significantly associated with the prognosis in patients who underwent TAVR. Further investigations with a larger sample size and longer follow-up period are required to establish a more robust prognostic prediction model.

**Study Limitations**

This study has several limitations. First, this was a single-center, retrospective study, and may have had selection bias, even though we enrolled patients consecutively. Second, the sample size was relatively small, attributable to which the statistical power was relatively low. To avoid type II errors, future studies must assess larger samples of patients. Third, the study population was limited to older, mainly female patients, affecting generalizability of our findings. Fourth, a single CT scanner vendor was used in the current study. The performance of ECV measured by using other CT vendors has not been assessed. Fifth, for the assessment of clinical events, we used reports from family members and telephone interviews in those patients who did not visit our institution for follow-up. Therefore, some recall bias may potentially have occurred. Finally, we did not screen other concomitant cardiomyopathies using imaging modalities such as CMR, scintigraphy, and myocardial biopsy, which may have caused ECV elevation.

**CONCLUSIONS**

Myocardial ECV using dual-energy CT was significantly associated with the composite outcomes of all-cause death and hospitalization for heart failure in patients with severe AS who underwent AVR. ECV measurements with CT obtained before AVR may be valuable for predicting prognosis in this population.

**ARTICLE INFORMATION**

Received December 22, 2020; accepted July 30, 2021.

**Affiliations**

Division of Cardiovascular Medicine, Department of Internal Medicine (M.S., T.T., Y.I., H.F., K.M., H.T., H.O., H.T., S.F., K.H.); Department of Radiology (Y.W., A.K.K.) and Division of Cardiovascular Surgery, Department of Surgery, Kobe University Graduate School of Medicine Japan, (K.O.).

**Acknowledgments**

We would like to thank Dr Tatsuya Nishii for helpful discussions. We are also grateful for the technical support provided by our radiological technologists: Asuka Sunakawa, Takuro Nishio, Tomoki Maebayashi, Akiko Fukutomi, Kyosumi Kagawa, and Noriyuki Negi.

**Sources of Funding**

None.

**Disclosures**

None.

**Supplementary Material**

Table S1–S3

**REFERENCES**

1. Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol. 2012;60:1854–1863. doi: 10.1016/j.jacc.2012.02.093
2. Weidemann F, Herrmann S, Störk S, Niemann M, Frantz S, Lange V, Beer M, Gattenlöchner S, Voelker W, Ertl G, et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation. 2009;120:577–584. doi: 10.1161/CIRCULATIONAHA.108.847772
3. Milano AD, Faggian G, Dodonov M, Golia G, Tomozzoli A, Bortolotti U, Mazzucco A. Prognostic value of myocardial fibrosis in patients with severe aortic valve stenosis. J Thorac Cardiovasc Surg. 2012;144:830–837. doi: 10.1016/j.jtcvs.2011.11.024
4. Hein S, Arnon E, Kostin S, Schönburg M, Elslässer A, Polyakova V, Bauer EP, Klövekorn W-P, Schaper J. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation. 2003;107:984–991. doi: 10.1161/01.CIR.0000051865.66123.87
5. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Killman P, Mascherbauer J, Nezafat R, Salerno M, Scheibert EB, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2 and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging. J Cardiovasc Magn Reson. 2017;19:1–24. doi: 10.1186/s12968-017-0389-8
6. Treibel TA, López B, González A, Menacho K, Schofield RS, Ravassa S, Fontana M, White SK, DiSalvo C, Roberts N, et al. Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. Eur Heart J. 2018;39:699–709. doi: 10.1093/eurheartj/ehx353
7. Park SJ, Cho SW, Kim SM, Ahn J, Carriere K, Jeong DS, Lee SC, Park SW, Choi YH, Park PW, et al. Assessment of myocardial fibrosis using multimodality imaging in severe aortic stenosis: comparison with histologic fibrosis. JACC Cardiovasc Imaging. 2019;12:109–119. doi: 10.1016/j.jcmg.2018.05.028
8. Everett RJ, Treibel TA, Fukui M, Lee H, Rigoli M, Singh A, Bijsterveld P, Tastet L, Musa TA, Dobson L, et al. Extracellular myocardial volume in patients with aortic stenosis. J Am Coll Cardiol. 2020;75:304–316. doi: 10.1016/j.jacc.2019.11.032
9. Allard M, Doucet D, Kien P, Bonnemain B, Caillé JM. Experimental study of DOTA-gadolinium pharmacokinetics and pharmacologic properties. Invest Radiol. 1988;23:S271–S274. doi: 10.1097/00004424-198809001-00059
10. Treibel TA, Bandula S, Fontana M, White SK, Gilbertson JA, Harrey AS, Gilmore JD, Punwani S, Hawkins PN, Taylor SA, et al. Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. J Cardiovasc Comput Tomogr. 2015;9:585–592. doi: 10.1016/j.jcct.2015.07.001
11. Lee HJ, Im DJ, Youn JC, Chang S, Suh YJ, Hong YJ, Kim YJ, Hur J, Choi BW. Myocardial extracellular volume fraction with dual-energy equilibrium contrast-enhanced cardiac CT in nonischemic cardiomyopathy: a prospective comparison with cardiac MR imaging. Radiology. 2018;289:49–57. doi: 10.1148/radiol.2018151299
12. Ohta Y, Kishimoto J, Kitao S, Yunaga H, Mukai-Yatagai N, Fujii S, Yamamoto K, Fukuda T, Ogawa T. Investigation of myocardial extracellular volume fraction in heart failure patients using iodine map with rapid-kV switching dual-energy CT: segmental comparison with MRI
18. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation (TAVI)/transcatheter aortic valve replacement (TAVR): an expert consensus document of the society of cardiovascular computed tomography. J Cardiovasc Comput Tomogr. 2019;13:e010358. doi: 10.1016/j.jcct.2019.12.032

19. van Assen M, De Cecco CN, Sahbaee P, Eid MH, Griffith LP, Bauer MJ, Savage RH, Varghese M, Oudkerk M, Vliegenthart R, et al. Feasibility of extracellular volume quantification using dual-energy CT. J Cardiovasc Comput Tomogr. 2019;13:81–84. doi: 10.1016/j.jcct.2019.10.011

20. Oda S, Kidoh M, Nakaura T, Nagayama Y, Sakabe D, Kakei K, Goto M, Funama Y, Hatemura M, et al. Myocardial extracellular volume calculation using cardiac computed tomography: a comparison of the dual-energy iodine method and the standard subtraction method. Acad Radiol. 2021;28:e119–e126. doi: 10.1016/j.acra.2020.03.019

21. Scully PR, Patel KP, Saberwal B, Klotz E, Augusto JB, Thornton GD, Hughes RK, Manisty C, Lloyd G, Newton JD, et al. Identifying cardiac amyloid in aortic stenosis ECV quantification by CT in TAVR patients. JACC Cardiovasc Imaging. 2020;13:2177–2189. doi: 10.1016/j.jcmg.2020.05.029

22. Oda S, Kidoh M, Takahio S, Inoue T, Nagayama Y, Nakaura T, Shiraiishi S, Tabata N, Usuku H, Kaikita K, et al. Quantification of myocardial extracellular volume with planning computed tomography for transcatheter aortic valve replacement to identify occult cardiac amyloidosis in patients with severe aortic stenosis. Circ Cardiovasc Imaging. 2020;13:e010358. doi: 10.1161/CIRCIMAGING.119.010358

23. van Assen M, De Cecco CN, Sahbaee P, Eid MH, Griffith LP, Bauer MJ, Savage RH, Varghese M, Oudkerk M, Vliegenthart R, et al. Feasibility of extracellular volume quantification using dual-energy CT. J Cardiovasc Comput Tomogr. 2019;13:81–84. doi: 10.1016/j.jcct.2019.10.011

24. Scharbatke JH, O’Brien JM, Earls JP, Min JK, LaBounty TM, Cury RC, Lee T-Y, So A, Hague CJ, Al-Hassan D, et al. Coronary artery imaging with single-source rapid kilovolt peak-switching dual-energy CT. Radiology. 2013;268:702–709. doi: 10.1148/radiol.131219101

25. Matsumoto K, Jinnoki M, Tanami Y, Ueno A, Yamada M, Kuribayashi S. Virtual monochromatic spectral imaging with fast kilovoltage switching: improved image quality as compared with that obtained with conventional 120-kVP CT. Radiology. 2011;259:257–262. doi: 10.1148/radiol.11100978

26. Flett AS, Sado DM, Quarta G, Mirabel M, Herrey AS, Hauensoy DJ, Antii C, Yap J, Kolvekar S, et al. Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2012;13:819–826. doi: 10.1016/j.ehjci.2012.03.012

27. Aggarwal SR, Clavel MA, Messika-Zeitoun D, Cuffe C, Malouf J, Araoz PA, Mankad R, Michelena H, Vahanian A, Enriquez-Sarano M. Sex differences in aortic valve calcification measured by multidetector computed tomography in aortic stenosis. Circ Cardiovasc Imaging. 2013;6:40–47. doi: 10.1161/CIRCIMAGING.112.980052

28. Scully PR, Treibel TA, Fontana M, Lloyd G, Mullen M, Pugliese F, Hartman N, Hawkins PN, Menezes LJ, Moon JC. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol. 2018;71:463–464. doi: 10.1016/j.jacc.2017.11.037

29. Castaño A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, Deluca A, Robin J, Chiuzan C, Nazil T, Vahi T, et al. Unveiling trans-thyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879–2887. doi: 10.1093/eurheartj/ehx350

30. Azevedo CF, Nigiri M, Higuchi ML, Pomerantz-PF, Spina GS, Sampao RO, Tarasoutchi F, Grinberg M, Rochitte CE. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol. 2010;56:278–287. doi: 10.1016/j.jacc.2009.12.074

31. Nadji J, Nieberler H, Hendrich E, Wil A, Pellegrini C, Husser O, Hengstenberg C, Greiser A, Martinoff S, Hamedatzky M. Prognostic value of T1-mapping in TAVR patients: extra-cellular volume as a possible predictor for peri-and post-TAVR adverse events. Int J Cardiovasc Imaging. 2016;32:1625–1633. doi: 10.1007/s10554-016-0948-3

32. Sawa Y, Takayama M, Goto T, Takanashi S, Komiyi T, Tobaru T, Maeda K, Kuratani T, Sakata Y. Five-Year Outcomes of the First Pivotal Clinical Trial of Balloon-Expandable Transcatheter Aortic Valve Replacement in Japan (PREVAIL JAPAN). Circ J. 2017;81:1102–1107. doi: 10.1253/circj.CJ-17-0111

33. Ishizu K, Shirai S, Isotani A, Hayashi M, Kawaguchi T, Taniguchi T, Ando K, Yashima F, Tada N, Yamawaki M, et al. Long-term prognostic value of the society of thoracic surgery risk score in patients undergoing transcatheter aortic valve implantation (from the OCEAN-TAVI Registry). Am J Cardiol. 2021;149:86–94. doi: 10.1016/j.amjcard.2021.03.027
SUPPLEMENTAL MATERIAL
Table S1. Patient characteristics between TAVR and SAVR groups.

|                          | TAVR group (n = 74) | SAVR group (n = 21) | p Value |
|--------------------------|---------------------|---------------------|---------|
| Age, years               | 85.0 ± 4.1          | 80.5 ± 6.2          | <0.001  |
| Female, n (%)            | 57 (77)             | 14 (67)             | 0.35    |
| Body mass index, kg/m²   | 22.7 ± 4.0          | 22.2 ± 2.9          | 0.58    |
| Body surface area, m²    | 1.41 ± 0.16         | 1.43 ± 0.17         | 0.73    |
| NYHA class III or IV     | 26 (35)             | 4 (19)              | 0.15    |
| STS-PROM score, %        | 5.67 (4.33–9.05)    | 7.93 (5.28–11.88)   | 0.049   |
| Hypertension, n (%)      | 52 (70)             | 18 (86)             | 0.14    |
| Dyslipidemia, n (%)      | 26 (35)             | 9 (43)              | 0.52    |
| Diabetes mellitus, n (%) | 14 (19)             | 6 (29)              | 0.35    |
| Chronic kidney disease, n (%) | 29 (39)   | 10 (48)             | 0.49    |
| Atrial fibrillation, n (%) | 13 (18)            | 3 (14)              | 0.72    |
| Previous PCI, n (%)      | 18 (24)             | 2 (10)              | 0.12    |
| Previous CABG, n (%)     | 2 (3)               | 0 (0)               | 0.31    |
| Previous myocardial infarction, n (%) | 5 (7)       | 0 (0)               | 0.11    |
| Implantable cardiac device, n (%) | 0 (0)     | 2 (10)              | 0.013   |
| Hematocrit, %            | 35.0 ± 4.4          | 36.5 ± 4.8          | 0.18    |
| Creatinine, mg/dl        | 0.83 (0.68–1.04)    | 0.88 (0.74–0.98)    | 0.66    |
| eGFR, ml/min/1.73m²      | 54.8 ± 17.1         | 53.9 ± 13.8         | 0.83    |
| BNP, pg/ml               | 292.4 (121.9–523.1) | 159.4 (82.3–550.3)  | 0.28    |
| LV end-diastolic volume, ml | 69.7 (54.6–88.7)   | 72.0 (50.2–92.5)    | 0.99    |
| LV end-systolic volume, ml | 24.2 (18.7–35.7)   | 24.7 (15.0–38.7)    | 0.95    |
| LVEF, %                  | 63.7 (56.0–70.6)    | 67.1 (54.6–71.7)    | 0.63    |
| LV mass, g               | 164.5 (139.7–214.7) | 149.5 (124.5–218.3) | 0.56    |
| E/e’ ratio               | 23.1 (16.8–29.4)    | 23.1 (14.8–39.9)    | 0.77    |
| Measure                                                   | Value 1 (Range)                    | Value 2 (Range)                    | P Value |
|-----------------------------------------------------------|-----------------------------------|-----------------------------------|---------|
| Peak aortic-jet velocity, cm/s                            | 450.3 (426.9–488.1)              | 456.9 (413.5–545.3)              | 0.74    |
| Mean aortic valve gradient, mm Hg                         | 51.5 ± 12.1                      | 51.3 ± 17.7                      | 0.96    |
| Aortic valve area, cm²                                     | 0.61 ± 0.15                      | 0.59 ± 0.21                      | 0.59    |
| Indexed aortic valve area, cm²/m²                         | 0.43 ± 0.11                      | 0.41 ± 0.14                      | 0.44    |
| Bicuspid aortic valve, n (%)                              | 2 (3)                            | 5 (24)                           | 0.004   |
| Low-flow, low-gradient subtype, n (%)                     | 6 (8)                            | 3 (14)                           | 0.41    |
| CT measures                                               |                                   |                                  |         |
| ECV, %                                                    | 28.3 ± 3.9                       | 27.4 ± 3.2                       | 0.36    |
| Aortic valve calcium score, AU                            | 2293.6 (1569.2–3305.6)           | 2378.3 (1928.8–3311.0)           | 0.72    |
| Clinical events                                           |                                   |                                  | 0.43    |
| Composite outcome*, n (%)                                 | 18 (24)                          | 4 (19)                           | 0.61    |
| All-cause death, n (%)                                    | 13 (18)                          | 2 (10)                           | 0.35    |
| Cardiac death, n (%)                                      | 5 (7)                            | 1 (5)                            | 0.73    |
| Hospitalization for heart failure, n (%)                  | 9 (12)                           | 2 (10)                           | 0.73    |

Values are mean ± standard deviation, n (%), or median (interquartile range). *Composite outcome defined as all-cause death or hospitalization for heart failure. P values < 0.05 are shown in **bold**.

AU, Agatston unit; BNP, B-type natriuretic peptide; CABG, coronary artery bypass grafting; CT, computed tomography; ECV, extracellular volume fraction; eGFR, estimated glomerular filtration rate; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SAVR, surgical aortic valve replacement; STS-PROM, Society of Thoracic Surgeons Predicted Risk of Mortality; TAVR, transcatheter aortic valve replacement.
Table S2. Univariable Cox regression analysis for composite outcome in TAVR group.

|                              | HR   | 95% CI       | p Value |
|------------------------------|------|--------------|---------|
| Age, years                   | 1.02 | 0.90–1.16    | 0.79    |
| Male                         | 1.59 | 0.60–4.24    | 0.37    |
| Body mass index, kg/m²       | 0.93 | 0.81–1.05    | 0.22    |
| NYHA class III or IV         | 2.74 | 1.05–7.15    | **0.041**|
| STS-PROM score, %            | 1.00 | 0.88–1.11    | 0.95    |
| Atrial fibrillation          | 1.74 | 0.56–5.39    | 0.36    |
| Coronary artery disease*     | 0.55 | 0.18–1.68    | 0.27    |
| Implantable cardiac device   | -    | -            | -       |
| BNP, pg/ml                   | 1.0006 | 0.9998–1.0012 | 0.12    |
| LVEF, %                      | 0.99 | 0.95–1.02    | 0.39    |
| LV mass, g                   | 1.00 | 0.99–1.01    | 0.36    |
| E/e’ ratio                   | 1.00 | 0.96–1.03    | 0.85    |
| Peak aortic-jet velocity, cm/s | 1.01 | 0.99–1.02 | 0.21 |
| Mean aortic valve gradient, mm Hg | 1.04 | 0.99–1.08 | 0.052 |
| Indexed aortic valve area, cm²/m² | 0.43 | 0.005–39.73 | 0.71 |
| Bicuspid aortic valve        | 2.51 | 0.33–19.06   | 0.43    |
| Low-flow, low-gradient subtype | 0.37 | 0.05–3.01  | 0.29    |
| ECV, %                       | 1.26 | 1.11–1.42    | **<0.001**|
| Aortic valve calcium score, AU | 1.0004 | 1.0000–1.0008 | **0.044** |

*Coronary artery disease defined as history of previous myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. P values < 0.05 are shown in **bold**.

AU, Agatston unit; BNP, B-type natriuretic peptide; CI, confidence interval; ECV, extracellular volume fraction; HR, hazard ratio; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; STS-PROM, Society of Thoracic Surgeons Predicted Risk of Mortality; TAVR, transcatheter aortic valve replacement.
Table S3. Univariable Cox regression analysis for composite outcome in SAVR group.

|                                      | Univariable | HR   | 95% CI      | p Value |
|--------------------------------------|-------------|------|-------------|---------|
| Age, years                           |             | 1.05 | 0.89–1.26   | 0.58    |
| Male                                 |             | 0.62 | 0.06–5.97   | 0.67    |
| Body mass index, kg/m²               |             | 0.71 | 0.44–1.06   | 0.098   |
| NYHA class III or IV                 |             | 4.36 | 0.61–31.08  | 0.16    |
| STS-PROM score, %                    |             | 1.27 | 1.05–1.62   | 0.014   |
| Atrial fibrillation                  |             | 20.16| 2.06–197.79 | 0.005   |
| Coronary artery disease*             |             | 1.86 | 0.26–13.3   | 0.54    |
| Implantable cardiac device           |             | 5.67 | 0.50–64.08  | 0.22    |
| BNP, pg/ml                           |             | 1.003| 0.999–1.006 | 0.12    |
| LVEF, %                              |             | 1.01 | 0.94–1.13   | 0.86    |
| LV mass, g                           |             | 0.98 | 0.96–1.00   | 0.11    |
| E/e’ ratio                           |             | 1.04 | 0.99–1.10   | 0.098   |
| Peak aortic-jet velocity, cm/s       |             | 0.99 | 0.98–1.00   | 0.096   |
| Mean aortic valve gradient, mm Hg    |             | 0.96 | 0.90–1.01   | 0.13    |
| Indexed aortic valve area, cm²/m²    |             | 19.39| 0.17–3003.84| 0.21    |
| Bicuspid aortic valve                |             | 0.88 | 0.09–8.51   | 0.91    |
| Low-flow, low-gradient subtype       |             | 20.47| 1.75–238.84 | 0.016   |
| ECV, %                               |             | 1.87 | 1.15–3.99   | 0.009   |
| Aortic valve calcium score, AU       |             | 0.9993| 0.9981–1.0002| 0.13    |

*Coronary artery disease defined as history of previous myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. P values < 0.05 are shown in **bold**. AU, Agatston unit; BNP, B-type natriuretic peptide; CI, confidence interval; ECV, extracellular volume fraction; HR, hazard ratio; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SAVR, surgical aortic valve replacement; STS-PROM, Society of Thoracic Surgeons Predicted Risk of Mortality.